Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,390.00    108.00 (4.73%)
Bid:
2,380.00
Ask:
2,384.00
Spread: 4.00 (0.168%)
Market Cap: £7.67b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

16 Dec 2020 07:00

RNS Number : 7724I
Bunzl PLC
16 December 2020
 

16 December 2020

 

BUNZL PRE-CLOSE STATEMENT AND ACQUISITION IN CANADA

 

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the year ending 31 December 2020.

 

The Group's resilient business model is expected to deliver a strong performance in the year ending 31 December 2020, with continued growth in Covid-19 related orders during the fourth quarter of the year against the background of increased pandemic-driven restrictions in some markets.

 

Group revenue for the year is expected to increase by approximately 8% at actual exchange rates and by approximately 9% at constant exchange rates, due to similar levels of growth from both the increase in organic revenue and the impact of acquisitions. Organic revenue growth continues to reflect diverging trends between the strength of Covid-19 related product sales, including a higher proportion of imported own brand products such as gloves, masks, sanitisers and disinfectants, and declines in the sales of other products. The Group expects the growth in Covid-19 related sales over the fourth quarter to be driven by the ongoing support of smaller orders, whilst larger orders will continue to slow. The decline in other product sales seen earlier in the year is expected to improve slightly despite the impact of recently strengthened pandemic-related restrictions in some markets. The Group operating margin in 2020 has continued to benefit significantly from the mix of products sold and is expected to be higher than the prior year.

 

Looking ahead, visibility remains limited on the future extent and duration of pandemic-related restrictions, the timing of the roll-out of vaccination programmes and the pandemic's macroeconomic impact. At constant exchange rates the Group expects revenue in 2021 to be lower than the current year with minimal benefit from larger Covid-19 related orders which have strongly supported the performance in 2020. The Group expects an underlying recovery in sales of other products to be broadly offset by a decline in smaller Covid-19 related orders, with acquisitions made during 2020 making a contribution to the Group's performance in 2021. Group operating margins are expected to return to more historical levels.

 

The Company also announces that it has recently completed the purchase of Snelling, a Canadian business focused on the sale of cleaning and hygiene products and industrial and foodservice packaging with revenue in 2019 of C$48 million (c.£28 million). Snelling principally supplies customers operating in the grocery, industrial and hospitality sectors throughout Eastern and Central Canada. In addition, further to the announcement on 9 November 2020, the Company also confirms that it has now completed the acquisition of SP Equipamentos, a leading personal protection equipment distributor based in Sao Paulo, Brazil, with revenue in 2019 of BRL143 million (c.£22 million).

 

 

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"The Group's performance during the pandemic has demonstrated the resilience of the Bunzl portfolio, the strength of our supply chain and the agility of our decentralised operating model. Growth through acquisitions continues to be an important part of our strategy and the new acquisitions demonstrate our continued success in attracting high quality businesses to join Bunzl. This year has been one of the most acquisitive in our history, with more than £410 million of committed spend. The acquisition pipeline remains active with a number of discussions ongoing."

 

 

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Tel: +44 (0)20 7725 5000

Tulchan

David Allchurch

Martin Robinson

Tel: +44 (0)20 7353 4200

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBIBDDRDBDGGU
Date   Source Headline
3rd Jun 202610:45 amRNSDirector/PDMR Shareholding
1st Jun 202610:15 amRNSTotal Voting Rights
1st Jun 202610:00 amRNSAdmission to Trading
8th May 20264:13 pmRNSDirector/PDMR Shareholding
7th May 20262:43 pmRNSDirector/PDMR Shareholding
6th May 202610:05 amRNSDirector/PDMR Shareholding
1st May 202611:15 amRNSTotal Voting Rights
22nd Apr 20264:15 pmRNSResult of AGM
22nd Apr 20267:00 amRNSTrading Statement
13th Apr 20264:00 pmRNSDirector/PDMR Shareholding
9th Apr 202612:01 pmRNSDirector/PDMR Shareholding
1st Apr 20264:00 pmRNSDirector/PDMR Shareholding
1st Apr 202611:00 amRNSTotal Voting Rights
31st Mar 20264:50 pmRNSDirector/PDMR Shareholding
20th Mar 20262:28 pmRNSDirector/PDMR Shareholding
18th Mar 20265:26 pmRNSDirector/PDMR Shareholding
17th Mar 20264:20 pmRNSAnnual Financial Report
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
10th Mar 20263:30 pmRNSDirector Declaration
10th Mar 20263:30 pmRNSDirector Declaration
9th Mar 202610:20 amRNSDirector/PDMR Shareholding
5th Mar 20265:15 pmRNSDirector/PDMR Shareholding
4th Mar 20264:00 pmRNSDirector/PDMR Shareholding
3rd Mar 20264:45 pmRNSDirector/PDMR Shareholding
2nd Mar 202611:00 amRNSTotal Voting Rights
2nd Mar 202610:00 amRNSDividend Declaration
2nd Mar 20267:00 amRNSFinal Results
3rd Feb 20265:00 pmRNSDirector/PDMR Shareholding
2nd Feb 202612:45 pmRNSTotal Voting Rights
13th Jan 20265:00 pmRNSDirector/PDMR Shareholding
7th Jan 20265:15 pmRNSDirector/PDMR Shareholding
6th Jan 202611:15 amRNSDirector/PDMR Shareholding
2nd Jan 202610:45 amRNSTotal Voting Rights
17th Dec 20257:00 amRNSTrading Statement
3rd Dec 202512:00 pmRNSDirector/PDMR Shareholding
1st Dec 202511:00 amRNSTotal Voting Rights
27th Nov 20259:00 amRNSAdditional Listing
26th Nov 20253:34 pmRNSPublication of Admission Particulars.
21st Nov 20255:30 pmRNSHolding(s) in Company
17th Nov 20255:34 pmRNSHolding(s) in Company
13th Nov 20259:00 amRNSAdditional Listing
5th Nov 20259:45 amRNSDirector/PDMR Shareholding
3rd Nov 20254:00 pmRNSHolding(s) in Company
3rd Nov 20253:29 pmRNSTotal Voting Rights
3rd Nov 20259:30 amRNSBlock listing Interim Review
3rd Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.